UK charity pockets $150 mln from Merck cancer immu**therapy drug
 

LONDON :British medical charity MRC Tech**logy has pocketed $150 million by selling part of its
royalty interest in Merck & Co´s successful cancer drug Keytruda, allowing it to plough fresh funds into new research.

The charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine.

Keytruda is one of a promising class of new treatments that stimulate the body´s immune system to fight cancer.

It is an antibody-based medicine and was "humanised" by scientists at MRC Tech**logy.

http://feeds.feedburner.com/~r/com/YEor/~4/fEzaa6aM-B4

أكثر...